Colm Keane

Colm Keane

Brisbane, QLD, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 69 publications

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.

Journal: British journal of haematology

Published: March 11, 2026

Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.

Checkpoint inhibitors, obinutuzumab plus PET-adapted ultra-low dose nodal radiotherapy yield high efficacy in treatment-naïve follicular lymphoma: Results from the phase II 'FLUORO' study.

Journal: British journal of haematology

Published: February 16, 2026

Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study.

Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study.

Journal: Blood neoplasia

Published: September 26, 2025

Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.

Advances in biomarkers for mantle cell lymphoma in the era of targeted therapies.

Journal: Haematologica

Published: July 24, 2025

Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI.

Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI.

Journal: Neuro-oncology advances

Published: June 27, 2025

Same-Slide Spatial Multiomics Integration with IN-DEPTH Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment.

Same-Slide Spatial Multiomics Integration with IN-DEPTH Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment.

Journal: Cancer discovery

Published: May 05, 2025

T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FL.

T-cell immune profile changes predict durable response to nivolumab-rituximab in treatment-naïve FL.

Journal: Blood neoplasia

Published: May 01, 2025

PASTA: versatile tyramide-oligonucleotide amplification for multimodal spatial biology.

PASTA: versatile tyramide-oligonucleotide amplification for multimodal spatial biology.

Journal: Nature methods

Published: April 02, 2025

T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial.

T-cell dysregulation informs radiotherapy-immunotherapy response in B-cell lymphoma: results from a phase 1 trial.

Journal: Blood advances

Published: March 14, 2025

Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival.

Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival.

Journal: Journal of the National Cancer Institute

Published: January 07, 2025

T-Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B-Cell Lymphoma.

T-Cell Receptor Repertoires Show Dynamic Variation Between Diagnosis and Relapse of Diffuse Large B-Cell Lymphoma.

Journal: EJHaem

Published: January 06, 2025

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.

Nivolumab and rituximab in treatment-naïve follicular lymphoma: the phase 2 1st FLOR study.

Journal: Blood advances

Published: November 27, 2024

Showing 1-12 of 69

Last Updated: 09/26/2026